- Trial phase
- Approved
- Time to market
- Already approved and marketed since 1985. All major depot formulations (1-month, 3-month, 6-month) are on the market globally.
- Why 3/10
- This is an already-approved, marketed drug with no pending FDA decision, pivotal trial readout, or regulatory catalyst. It is one of many mature products in Takeda's broad commercial portfolio. The defining binary (initial FDA approval) passed decades ago, and all subsequent formulation extensions are also approved and commercialized. No dated binary catalyst exists.
Leuprorelin acetate is a mature, off-patent product for Takeda. Watch for generic erosion in Takeda's Japan and EU revenue disclosures during quarterly earnings, but there is no single binary catalyst for this drug that would move TAK shares. Takeda's next major pipeline catalysts include the Phase 3 readout for zasocitinib and the ongoing commercial launch of ORZEYFUL (oveporexton) and MIMRYLO (rusfertide), which are far more material to the stock.
Price Chart
Executive Summary
LEUPLINENANTONE is not a single drug but a concatenation of two Takeda brand names (Leuplin in Japan, Enantone in Europe) for the same active ingredient: leuprorelin acetate (leuprolide), a GnRH agonist used to suppress sex hormones in prostate cancer, premenopausal breast cancer, endometriosis, and uterine fibroids. Originally developed through the Takeda-Abbott partnership (TAP) and first FDA-approved in 1985 as Lupron, this is a mature, off-patent product facing generic competition. For Takeda (NYSE: TAK), a diversified global pharma company with a market cap around $60B+, leuprorelin products are a small part of a broad portfolio. There are no upcoming binary catalysts for this drug; Takeda's stock is driven by newer pipeline assets like zasocitinib, ORZEYFUL, and MIMRYLO.
How It Works
Leuprorelin acetate is a synthetic hormone that mimics a natural hormone called GnRH. Initially it causes a temporary surge in sex hormone production (testosterone in men, estrogen in women), but with continued use it shuts down the pituitary gland's signal, dramatically reducing those hormone levels. This chemical castration effect is used to treat hormone-driven cancers like prostate cancer and premenopausal breast cancer, as well as endometriosis and uterine fibroids. It is given as a slow-release injection that can last from 1 to 6 months per dose.
Trial Status
Leuprorelin acetate is a mature, approved drug. It continues to be studied in investigator-sponsored trials exploring new combinations and indications (e.g., neoadjuvant use in prostate cancer with darolutamide), but Takeda has no registrational trials running for this molecule. The active ingredient's patent protection has expired and multiple generic versions are available globally.
The Two-Sided Case
Upcoming Catalysts
- None for this specific drug. For Takeda broadly: Capital Markets Day on December 11, 2026 in Tokyo; ongoing regulatory reviews for zasocitinib; commercial launch trajectory for ORZEYFUL (oveporexton) and MIMRYLO (rusfertide).
Source Filing
The SecBot filing or press-release report that triggered this drug report:
TAKEDA PHARMACEUTICAL CO LTD 6-K TAK ·Originating report